ANAPLASTIC LARGE CELL LYMPHOMA IN ADULTS: RESULTS AND NEW APPROACH OF TREATMENT
(Abstract release date: 05/19/16)
EHA Library. Gorenkova L. 06/09/16; 134592; PB1692
Dr. Liliya Gorenkova
Contributions
Contributions
Abstract
Abstract: PB1692
Type: Publication Only
Background
Anaplastic Large Cell Lymphoma (ALCL) represents supgroupe of peripheral T-cell lymphoma and constitutes 10-12% of this groupe. According to WHO classification 2008 ALCL is subdivided by two types depending on presence of ALK gene rearrangement: ALK-positive (ALCL ALK+) and ALK-negative (ALCL ALK-). ALCL ALK+ has a favorable prognosis with CHOP in patients without adverse prognostic factors and event free survival (EFS) reaches 70-75%. ALCL ALK- has worse treatment results: when using CHOP overall survival (OS) and EFS doesn't reach more than 50%. Autologous stem cell transplantation (auto-SCT) in first complete remission takes an advantage.
Aims
to estimate an efficacy of intensive chemotherapy in treatment of ALCL ALK+ and ALCL ALK-
Methods
The study included 64 patients with ALCL (38 ALCL ALK+ 26 ALCL ALK-)
Results
36 patients with ALCL ALK+ were treated according NHL BFM-90: OS and relapse-free survival were 90% and 83%, respectively, median survival was 67 months.In 16 patients with ALCL ALK- was used NHL-BFM-90 protocol – common response (CO) was achieved in 8 from 16 patients (50%), however 6 patients had disease progression and 3 had a relapse. Thus, OS and EFS were 37,5% and 31% respectively. 8 patients were treated by TL-REZ-09 protocol. Complete/partial remission were acieved in 4 patients, 3 had disease progression. The highest efficacy was observed in 5 patients underwent auto-SCT in first complete remission: 4 from 5 patients alive in remission and one in relapse.
Conclusion
Patients with ALCL ALK+ have favorable prognosis and high treatment results on NHL BFM-90 protocol. Selection of induction chemotherapy regimen before auto-SCT in patients with ALCL ALK- continue to be unsolved question. In patients who didn't achieve a common response like second line therapy could be DexaBEAM protocol with subsequent auto-SCT.
Session topic: E-poster
Keyword(s): Anaplastic large cell lymphoma, Autologous hematopoietic stem cell transplantation, Treatment
Type: Publication Only
Background
Anaplastic Large Cell Lymphoma (ALCL) represents supgroupe of peripheral T-cell lymphoma and constitutes 10-12% of this groupe. According to WHO classification 2008 ALCL is subdivided by two types depending on presence of ALK gene rearrangement: ALK-positive (ALCL ALK+) and ALK-negative (ALCL ALK-). ALCL ALK+ has a favorable prognosis with CHOP in patients without adverse prognostic factors and event free survival (EFS) reaches 70-75%. ALCL ALK- has worse treatment results: when using CHOP overall survival (OS) and EFS doesn't reach more than 50%. Autologous stem cell transplantation (auto-SCT) in first complete remission takes an advantage.
Aims
to estimate an efficacy of intensive chemotherapy in treatment of ALCL ALK+ and ALCL ALK-
Methods
The study included 64 patients with ALCL (38 ALCL ALK+ 26 ALCL ALK-)
Results
36 patients with ALCL ALK+ were treated according NHL BFM-90: OS and relapse-free survival were 90% and 83%, respectively, median survival was 67 months.In 16 patients with ALCL ALK- was used NHL-BFM-90 protocol – common response (CO) was achieved in 8 from 16 patients (50%), however 6 patients had disease progression and 3 had a relapse. Thus, OS and EFS were 37,5% and 31% respectively. 8 patients were treated by TL-REZ-09 protocol. Complete/partial remission were acieved in 4 patients, 3 had disease progression. The highest efficacy was observed in 5 patients underwent auto-SCT in first complete remission: 4 from 5 patients alive in remission and one in relapse.
Conclusion
Patients with ALCL ALK+ have favorable prognosis and high treatment results on NHL BFM-90 protocol. Selection of induction chemotherapy regimen before auto-SCT in patients with ALCL ALK- continue to be unsolved question. In patients who didn't achieve a common response like second line therapy could be DexaBEAM protocol with subsequent auto-SCT.
Session topic: E-poster
Keyword(s): Anaplastic large cell lymphoma, Autologous hematopoietic stem cell transplantation, Treatment
Abstract: PB1692
Type: Publication Only
Background
Anaplastic Large Cell Lymphoma (ALCL) represents supgroupe of peripheral T-cell lymphoma and constitutes 10-12% of this groupe. According to WHO classification 2008 ALCL is subdivided by two types depending on presence of ALK gene rearrangement: ALK-positive (ALCL ALK+) and ALK-negative (ALCL ALK-). ALCL ALK+ has a favorable prognosis with CHOP in patients without adverse prognostic factors and event free survival (EFS) reaches 70-75%. ALCL ALK- has worse treatment results: when using CHOP overall survival (OS) and EFS doesn't reach more than 50%. Autologous stem cell transplantation (auto-SCT) in first complete remission takes an advantage.
Aims
to estimate an efficacy of intensive chemotherapy in treatment of ALCL ALK+ and ALCL ALK-
Methods
The study included 64 patients with ALCL (38 ALCL ALK+ 26 ALCL ALK-)
Results
36 patients with ALCL ALK+ were treated according NHL BFM-90: OS and relapse-free survival were 90% and 83%, respectively, median survival was 67 months.In 16 patients with ALCL ALK- was used NHL-BFM-90 protocol – common response (CO) was achieved in 8 from 16 patients (50%), however 6 patients had disease progression and 3 had a relapse. Thus, OS and EFS were 37,5% and 31% respectively. 8 patients were treated by TL-REZ-09 protocol. Complete/partial remission were acieved in 4 patients, 3 had disease progression. The highest efficacy was observed in 5 patients underwent auto-SCT in first complete remission: 4 from 5 patients alive in remission and one in relapse.
Conclusion
Patients with ALCL ALK+ have favorable prognosis and high treatment results on NHL BFM-90 protocol. Selection of induction chemotherapy regimen before auto-SCT in patients with ALCL ALK- continue to be unsolved question. In patients who didn't achieve a common response like second line therapy could be DexaBEAM protocol with subsequent auto-SCT.
Session topic: E-poster
Keyword(s): Anaplastic large cell lymphoma, Autologous hematopoietic stem cell transplantation, Treatment
Type: Publication Only
Background
Anaplastic Large Cell Lymphoma (ALCL) represents supgroupe of peripheral T-cell lymphoma and constitutes 10-12% of this groupe. According to WHO classification 2008 ALCL is subdivided by two types depending on presence of ALK gene rearrangement: ALK-positive (ALCL ALK+) and ALK-negative (ALCL ALK-). ALCL ALK+ has a favorable prognosis with CHOP in patients without adverse prognostic factors and event free survival (EFS) reaches 70-75%. ALCL ALK- has worse treatment results: when using CHOP overall survival (OS) and EFS doesn't reach more than 50%. Autologous stem cell transplantation (auto-SCT) in first complete remission takes an advantage.
Aims
to estimate an efficacy of intensive chemotherapy in treatment of ALCL ALK+ and ALCL ALK-
Methods
The study included 64 patients with ALCL (38 ALCL ALK+ 26 ALCL ALK-)
Results
36 patients with ALCL ALK+ were treated according NHL BFM-90: OS and relapse-free survival were 90% and 83%, respectively, median survival was 67 months.In 16 patients with ALCL ALK- was used NHL-BFM-90 protocol – common response (CO) was achieved in 8 from 16 patients (50%), however 6 patients had disease progression and 3 had a relapse. Thus, OS and EFS were 37,5% and 31% respectively. 8 patients were treated by TL-REZ-09 protocol. Complete/partial remission were acieved in 4 patients, 3 had disease progression. The highest efficacy was observed in 5 patients underwent auto-SCT in first complete remission: 4 from 5 patients alive in remission and one in relapse.
Conclusion
Patients with ALCL ALK+ have favorable prognosis and high treatment results on NHL BFM-90 protocol. Selection of induction chemotherapy regimen before auto-SCT in patients with ALCL ALK- continue to be unsolved question. In patients who didn't achieve a common response like second line therapy could be DexaBEAM protocol with subsequent auto-SCT.
Session topic: E-poster
Keyword(s): Anaplastic large cell lymphoma, Autologous hematopoietic stem cell transplantation, Treatment
{{ help_message }}
{{filter}}